Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies

M. Juliana McElrath(Fred Hutch Cancer Center), Lamar Ballweber-Fleming(Fred Hutch Cancer Center), Leonidas Stamatatos(University of Washington), Kellie J. MacPhee(Fred Hutch Cancer Center), David C. Montefiori(Duke University), Vanessa Rubin(Fred Hutch Cancer Center), Amanda S. Woodward Davis(Fred Hutch Cancer Center), Mingchao Shen(Fred Hutch Cancer Center), Srilatha Edupuganti(Emory University), Latha Kallur Siddaramaiah(Fred Hutch Cancer Center), John P. Moore(Cornell University), K. Rachael Parks(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Janine Maenza(Fred Hutch Cancer Center), Georgia D. Tomaras(National Institutes of Health), Nadine Rouphael(Emory University), Michael C. Keefer(University of Rochester), Gabriel Ozorowski(Scripps Research Institute), Holly Janes(Fred Hutch Cancer Center), Hannah L. Turner(Scripps Research Institute), Antu Dey(International AIDS Vaccine Initiative), Mark A. Tomai(3M (United States)), Michael Duff(Fred Hutch Cancer Center), Lawrence Corey(Fred Hutch Cancer Center), Dalton C. Karlinsey(Scripps Research Institute), Ian Frank(Norwegian Womens Public Health Association), Andrew B. Ward(Scripps Research Institute), Wen-Hsin Lee(Scripps Research Institute), Sarah Furth(Fred Hutch Cancer Center), Rogier W. Sanders(Scripps Research Institute), Ollivier Hyrien(Fred Hutch Cancer Center), Aaron Seese(Fred Hutch Cancer Center), Lindsey R. Baden(Brigham and Women's Hospital), Leigh M. Sewall(Scripps Research Institute), Stephen C. De Rosa(University of Washington), Zachary K. Sagawa(Access to Wholistic and Productive Living Institute), Chris Duplessis(National Institute of Allergy and Infectious Diseases)
The Journal of Experimental Medicine
August 17, 2024
Cited by 28


Related Papers